This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/pfizer-gsk-rsv-fda-approval-20cfd9cf

FDA Panel Says Pfizer’s RSV Vaccine Is Safe and Effective

By
Josh Nathan-Kazis
  • Order Reprints
  • Print Article

The Food and Drug Administration’s vaccines advisory committee on Tuesday said Pfizer ‘s data showed that its respiratory syncytial virus is safe and effective for older adults.

The vote passed narrowly, however, and the advisers raised concerns that the agency’s staff will need to contend with as they decide whether to approve the vaccine.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.